SNDX
Bearish signalScored 2026-11-01 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Syndax Pharmaceuticals, Inc.
- Nom
- Syndax Pharmaceuticals, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $1.2B
- Employés
- 298
- PDG
- Michael A. Metzger
- Site web
- https://www.syndax.com
- Marché
- ALXOCTMXMGNXNRIXNUVBORIC
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 8 000 titres (~113 716,00 $ US)
- Insiders
- Podlesak Dennis
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$113,716
Avg sell (VWAP, 90d window) $14.21 vs last close $13.65 (-4.0%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-10-29
- Liquidity
- Liquid $37,741,467/day · 20d vol
- Last synced
-
2026-11-01 11:35:13
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-29 | Podlesak Dennis | Sell · S S · 10b5-1: not stated | 8,000 | $14.21 | ≈ $113,716 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-11-01 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
SNDX presents a deeply unfavorable risk/reward profile: severe financial distress (liquidity score 45, fundamentals trend score 15) combined with a weak catalyst score (35) driven by fraud investigations, insider…
The first sentence of the analysis written for SNDX on 2026-11-01 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 4.40 · operating margin -158% — readings disagree
Suggested stop 12.44, 1.5 ATR under the last close(8.8% under the last close). Reward/risk to the next stored resistance is 5.12. Research, not advice. Not an order.
Recent news
- 2026-10-30 Syndax''s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases - Revuforj is the first and only menin inhibitor that is approved for adults and children one year and older with R/R NPM1m AML and KMT2A translocated acute leukemia -
- 2026-10-30 Syndax Announces Participation in November Investor Conferences NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
- 2026-10-29 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (NASDAQ: SNDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
- 2026-10-26 Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Syndax (SNDX) doesn''t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 2026-10-26 Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026 NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2026 financial results and provide a business update on Monday, November 2, 2026.
- 2026-10-26 Syndax Pharmaceuticals (SNDX) Set to Announce Quarterly Earnings on Monday Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect Syndax Pharmaceuticals to post earnings of ($0.4848) per share and revenue of $81.91 million for the quarter. Individuals may visit the company''s upcoming Q3 2026 earnings results page for
- 2026-10-21 Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Syndax Pharmaceuticals (NASDAQ:SNDX) BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) and Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk. Institutional and Insider Ownership 85.9% of BioCryst Pharmaceuticals
- 2026-10-17 SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law [url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
- 2026-10-17 SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $SNDX--SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
- 2026-10-15 Syndax''s Revuforj® (revumenib) Named to TIME''s Best Inventions of 2026 List NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib), the Company''s first-in-class menin inhibitor, has been selected by TIME as one of the “Best Inventions of 2026” in the Medical and Healthcare category. TIME''s annual list of the Best Inventions features 300 extraordinary inventions changing lives.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 96.0% | 96.5% | 0.0% | 0.0% | 100.0% | |
| Ebit Margin | -146.0% | -1325.3% | 0.0% | 0.0% | 19.2% | |
| Ebitda Margin | -146.0% | -1325.3% | 0.0% | 0.0% | 19.2% | |
| Operating Profit Margin | -158.4% | -1434.4% | 0.0% | 0.0% | 18.8% | |
| Pretax Profit Margin | -165.6% | -1346.1% | 0.0% | 0.0% | 17.8% | |
| Continuous Operations Profit Margin | -165.6% | -1346.1% | 0.0% | 0.0% | 17.8% | |
| Net Profit Margin | -165.6% | -1346.1% | 0.0% | 0.0% | 17.8% | |
| Bottom Line Profit Margin | -165.6% | -1346.1% | 0.0% | 0.0% | 17.8% | |
| Current Ratio | 4.396 | 5.824 | 9.999 | 16.851 | 21.679 | |
| Quick Ratio | 4.124 | 5.820 | 9.999 | 16.851 | 21.679 | |
| Solvency Ratio | -0.614 | -0.730 | -3.567 | -5.012 | 0.605 | |
| Cash Ratio | 1.123 | 1.488 | 5.085 | 2.558 | 10.732 | |
| Price To Earnings Ratio | -6.386 | -3.544 | -7.252 | -10.346 | 45.604 | |
| Price To Earnings Growth Ratio | 0.541 | -0.141 | -0.343 | 0.017 | -0.359 | |
| Forward Price To Earnings Growth Ratio | 0.541 | -0.141 | -0.343 | 0.017 | -0.359 | |
| Price To Earnings Diluted Ratio | -6.386 | -3.544 | -7.252 | -10.346 | 45.604 | |
| Price To Earnings Diluted Growth Ratio | 0.541 | -0.141 | -0.343 | 0.017 | -0.359 | |
| Price To Book Ratio | 28.160 | 3.929 | 2.744 | 3.308 | 2.791 | |
| Price To Sales Ratio | 10.560 | 47.801 | 0.000 | 0.000 | 8.158 | |
| Price To Free Cash Flow Ratio | -5.632 | -4.118 | -9.469 | -11.549 | 39.297 | |
| Price To Operating Cash Flow Ratio | -5.635 | -4.118 | -9.469 | -11.568 | 39.123 | |
| Debt To Assets Ratio | 0.654 | 0.477 | 0.003 | 0.002 | 0.047 | |
| Debt To Equity Ratio | 5.361 | 1.200 | 0.003 | 0.002 | 0.051 | |
| Debt To Capital Ratio | 0.843 | 0.545 | 0.003 | 0.002 | 0.049 | |
| Long Term Debt To Capital Ratio | 0.842 | 0.535 | 0.000 | 0.000 | 0.046 | |
| Financial Leverage Ratio | 8.196 | 2.516 | 1.106 | 1.064 | 1.101 | |
| Working Capital Turnover Ratio | 0.380 | 0.046 | 0.000 | 0.000 | 0.395 | |
| Operating Cash Flow Ratio | -2.689 | -2.655 | -2.764 | -4.599 | 1.408 | |
| Operating Cash Flow Sales Ratio | -1.874 | -11.609 | 0.000 | 0.000 | 0.209 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.000 | 1.000 | 1.002 | 0.996 | |
| Debt Service Coverage Ratio | -7.448 | -18.411 | -1,005.481 | -46.595 | 14.148 | |
| Interest Coverage Ratio | -8.083 | -68.913 | -1,105.548 | -48.376 | 13.807 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -22.689 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.932 | -0.795 | -98.227 | -115.138 | 1.389 | |
| Capital Expenditure Coverage Ratio | -1,727.166 | 0.000 | 0.000 | -594.111 | 225.822 | |
| Dividend Paid And Capex Coverage Ratio | -1,727.166 | 0.000 | 0.000 | -594.111 | 225.822 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -8.074 | -4.218 | -5.867 | -10.079 | 34.938 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 96.0% | ▼-0.6% | ▲37.5% |
| Ebit Margin | -146.0% | ▲1179.3% | ▲144.4% |
| Ebitda Margin | -146.0% | ▲1179.3% | ▲144.4% |
| Operating Profit Margin | -158.4% | ▲1276.0% | ▲156.4% |
| Pretax Profit Margin | -165.6% | ▲1180.5% | ▲133.2% |
| Continuous Operations Profit Margin | -165.6% | ▲1180.5% | ▲133.2% |
| Net Profit Margin | -165.6% | ▲1180.5% | ▲133.2% |
| Bottom Line Profit Margin | -165.6% | ▲1180.5% | ▲133.2% |
| Current Ratio | 4.396 | ▼-1.427 | ▼-7.354 |
| Quick Ratio | 4.124 | ▼-1.697 | ▼-7.571 |
| Solvency Ratio | -0.614 | ▲0.116 | ▲1.250 |
| Cash Ratio | 1.123 | ▼-0.365 | ▼-3.074 |
| Price To Earnings Ratio | -6.386 | ▼-2.842 | ▼-10.001 |
| Price To Earnings Growth Ratio | 0.541 | ▲0.682 | ▲0.598 |
| Forward Price To Earnings Growth Ratio | 0.541 | ▲0.682 | ▲0.598 |
| Price To Earnings Diluted Ratio | -6.386 | ▼-2.842 | ▼-10.001 |
| Price To Earnings Diluted Growth Ratio | 0.541 | ▲0.682 | ▲0.598 |
| Price To Book Ratio | 28.160 | ▲24.232 | ▲19.974 |
| Price To Sales Ratio | 10.560 | ▼-37.241 | ▼-2.744 |
| Price To Free Cash Flow Ratio | -5.632 | ▼-1.514 | ▼-7.338 |
| Price To Operating Cash Flow Ratio | -5.635 | ▼-1.518 | ▼-7.302 |
| Debt To Assets Ratio | 0.654 | ▲0.177 | ▲0.418 |
| Debt To Equity Ratio | 5.361 | ▲4.161 | ▲4.037 |
| Debt To Capital Ratio | 0.843 | ▲0.297 | ▲0.554 |
| Long Term Debt To Capital Ratio | 0.842 | ▲0.307 | ▲0.557 |
| Financial Leverage Ratio | 8.196 | ▲5.680 | ▲5.399 |
| Working Capital Turnover Ratio | 0.380 | ▲0.334 | ▲0.216 |
| Operating Cash Flow Ratio | -2.689 | ▼-0.034 | ▼-0.429 |
| Operating Cash Flow Sales Ratio | -1.874 | ▲9.735 | ▲0.781 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | ▲0.001 | ▲0.001 |
| Debt Service Coverage Ratio | -7.448 | ▲10.963 | ▲205.309 |
| Interest Coverage Ratio | -8.083 | ▲60.830 | ▲235.340 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲22.689 | ▲4.538 |
| Operating Cash Flow Coverage Ratio | -0.932 | ▼-0.137 | ▲41.808 |
| Capital Expenditure Coverage Ratio | -1727.166 | ▼-1727.166 | ▼-1308.075 |
| Dividend Paid And Capex Coverage Ratio | -1727.166 | ▼-1727.166 | ▼-1308.075 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -8.074 | ▼-3.856 | ▼-9.414 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.82B | $1.13B | $1.52B | $1.55B | $1.14B | |
| Enterprise value | $2.03B | $1.32B | $1.23B | $1.47B | $938.7M | |
| EV / Sales | 11.79x | 55.89x | 0.00x | 0.00x | 6.72x | |
| EV / Op. cash flow | -6.29x | -4.82x | -7.64x | -11.02x | 32.22x | |
| EV / Free cash flow | -6.29x | -4.82x | -7.64x | -11.00x | 32.37x | |
| EV / EBITDA | -8.07x | -4.22x | -5.87x | -10.08x | 34.94x | |
| Net debt / EBITDA | -0.84x | -0.61x | 1.41x | 0.50x | -7.48x | |
| Current ratio | 4.40x | 5.82x | 10.00x | 16.85x | 21.68x | |
| Income quality | 1.13x | 0.86x | 0.77x | 0.90x | 1.17x | |
| Graham number | — | — | — | — | $9 | |
| Graham net-net | $0 | $2 | $7 | $8 | $8 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 113.4% | 101.6% | 100.1% | 102.1% | 92.9% | |
| Working capital | $408.0M | $499.5M | $522.8M | $460.7M | $427.7M | |
| Invested capital | $409.5M | $501.5M | $524.3M | $461.8M | $429.0M | |
| Return on assets | -53.9% | -44.0% | -34.2% | -30.0% | 5.5% | |
| Operating ROA | -43.5% | -50.8% | -41.4% | -32.1% | 7.0% | |
| Return on tangible assets | -53.9% | -44.0% | -34.2% | -30.0% | 5.5% | |
| Return on equity | -441.6% | -110.6% | -37.8% | -31.9% | 6.1% | |
| Return on invested capital | -66.6% | -53.6% | -41.4% | -32.4% | 6.1% | |
| Return on capital employed | -66.7% | -54.7% | -41.4% | -32.4% | 6.1% | |
| Earnings yield | -15.7% | -28.2% | -13.8% | -9.7% | 2.2% | |
| Free cash flow yield | -17.8% | -24.3% | -10.6% | -8.7% | 2.5% | |
| Capex / Op. cash flow | -0.1% | 0.0% | 0.0% | -0.2% | 0.4% | |
| Capex / Depreciation | 3116.7% | 0.0% | 0.0% | 681.8% | 300.0% | |
| Capex / Sales | 0.1% | 0.0% | 0.0% | 0.0% | 0.1% | |
| SG&A / Sales | 104.3% | 510.5% | 0.0% | 0.0% | 18.1% | |
| R&D / Sales | 150.1% | 1020.5% | 0.0% | 0.0% | 63.2% | |
| Stock comp / Sales | 27.6% | 181.7% | 0.0% | 0.0% | 9.5% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 149d | 214d | 0d | 0d | 1d | |
| Days payables outstanding | 868d | 5137d | 0d | 0d | 0d | |
| Operating cycle | 1864d | 376d | 0d | 0d | 1d | |
| Cash conversion cycle | 996d | -4762d | 0d | 0d | 1d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years